MedTrace Logo

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

NCT05707286 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2026-01-07

No results posted yet for this study

Summary

This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy.

Conditions

  • Melanoma
  • Gastrointestinal Neoplasms
  • Genitourinary Cancer
  • Thoracic Cancer
  • Sarcoma

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Indiana University

    lead OTHER

Principal Investigators

  • Tyler Shugg, PharmD, PhD · Indiana University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-07
Primary Completion
2025-01-20
Completion
2025-01-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05707286 on ClinicalTrials.gov